Dallas 2K (D2K) Study
Not all depressed patients respond well to the same treatments, so it’s important to identify the right treatment for the right patient as quickly as possible. In order to replace the current “trial and error method” of treating depression, we hope to identify biosignatures – a collection of genetic, clinical, demographic, behavioral, and biological markers to determine which treatment methods might be best for individual patients.
Major depression will affect 1 in 20 individuals in the United States this year and is the leading cause of disability worldwide. Increased depression severity is associated with poorer work productivity, functioning, general health, quality of life, life satisfaction, and well-being. To date, there are no effective biological methods to diagnose and assess depression or treatment response.
The Dallas 2K study is a long-term study researching the biological mechanisms of depression and antidepressant treatment response. The D2K study is comprised of 2,000 participants, over 10 years of age, with a lifetime or current diagnosis of a mood disorder. Researchers will collect socio-demographic and clinical data, cognitive and psychological assessments, fluid-based biomarkers (blood, urine, saliva), neuroimaging, and EEG. With this information, we hope to create a biosignature to aid in treatment selection and to identify a universal test for depression.